Chemotherapy and Targeted Therapy

The Psychedelic Paradox: Are We Overestimating the Efficacy of Psilocybin? the-psychedelic-paradox-are-we-overestimating-the-efficacy-of-psilocybin

The Psychedelic Paradox: Are We Overestimating the Efficacy of Psilocybin?

Nana Wu July 16, 2026

For years, the narrative surrounding classic psychedelics—particularly psilocybin—has been one of profound, almost miraculous transformation. In the...

Biopharma Mid-Year Pulse: J&J Earnings, Strategic M&A, and the Rise of AI-Driven Drug Discovery biopharma-mid-year-pulse-jj-earnings-strategic-ma-and-the-rise-of-ai-driven-drug-discovery

Biopharma Mid-Year Pulse: J&J Earnings, Strategic M&A, and the Rise of AI-Driven Drug Discovery

Muslim July 16, 2026

By Ben Fidler | Published July 15, 2026 The mid-point of 2026 has proven to be a...

Merck’s ADC Strategy Gains Momentum: Positive Clinical Data Bolsters Sac-TMT as a Future Cancer Standard mercks-adc-strategy-gains-momentum-positive-clinical-data-bolsters-sac-tmt-as-a-future-cancer-standard

Merck’s ADC Strategy Gains Momentum: Positive Clinical Data Bolsters Sac-TMT as a Future Cancer Standard

Ammar Sabilarrohman July 15, 2026

In the high-stakes world of oncology research, Merck & Co. has reached a pivotal juncture in its...

From Diabetes to MASH: How the GLP-1 Revolution is Redefining the Biobanking Landscape from-diabetes-to-mash-how-the-glp-1-revolution-is-redefining-the-biobanking-landscape-1

From Diabetes to MASH: How the GLP-1 Revolution is Redefining the Biobanking Landscape

Nana July 15, 2026

The pharmaceutical landscape has been fundamentally reshaped by the meteoric rise of GLP-1 receptor agonists. What began...

Draig Therapeutics Secures $65M Series B to Advance "Best-in-Disease" Psychiatric Pipeline draig-therapeutics-secures-65m-series-b-to-advance-best-in-disease-psychiatric-pipeline

Draig Therapeutics Secures $65M Series B to Advance "Best-in-Disease" Psychiatric Pipeline

Jia Lissa July 15, 2026

By Delilah Alvarado Published July 14, 2026 In a significant vote of confidence for the resurgence of...

Moderna’s Second Act: Betting on In Vivo CAR-T, Oncology, and the ‘Lucy’ AI Engine modernas-second-act-betting-on-in-vivo-car-t-oncology-and-the-lucy-ai-engine

Moderna’s Second Act: Betting on In Vivo CAR-T, Oncology, and the ‘Lucy’ AI Engine

Dwi Wanna July 15, 2026

Moderna, the biotechnology giant that became a household name through its rapid development of mRNA-based COVID-19 vaccines,...

Convergence at the Crescent City: AAPS PharmSci 360 2026 Set to Define the Future of Drug Development convergence-at-the-crescent-city-aaps-pharmsci-360-2026-set-to-define-the-future-of-drug-development

Convergence at the Crescent City: AAPS PharmSci 360 2026 Set to Define the Future of Drug Development

Lina Irawan July 14, 2026

The pharmaceutical landscape is currently undergoing a paradigm shift driven by the rapid integration of artificial intelligence,...

The New Economics of Medicine: How Most-Favored-Nation Pricing is Reshaping Generic Drug Strategy the-new-economics-of-medicine-how-most-favored-nation-pricing-is-reshaping-generic-drug-strategy

The New Economics of Medicine: How Most-Favored-Nation Pricing is Reshaping Generic Drug Strategy

Ali Ikhwan July 14, 2026

The pharmaceutical landscape in the United States is undergoing a profound structural transformation. As policymakers intensify their...

The Future of Colorectal Cancer Screening: Freenome and Abbott’s High-Stakes Path to Market Dominance the-future-of-colorectal-cancer-screening-freenome-and-abbotts-high-stakes-path-to-market-dominance

The Future of Colorectal Cancer Screening: Freenome and Abbott’s High-Stakes Path to Market Dominance

Sagoh July 13, 2026

The landscape of colorectal cancer (CRC) screening is undergoing a seismic shift. As the medical community pushes...

Evolution in B2B Media: WTWH Media Rebrands as Arrowfly to Reflect Expanded Market Presence evolution-in-b2b-media-wtwh-media-rebrands-as-arrowfly-to-reflect-expanded-market-presence

Evolution in B2B Media: WTWH Media Rebrands as Arrowfly to Reflect Expanded Market Presence

Ammar Sabilarrohman July 13, 2026

CLEVELAND, OH — In a move signaling both a maturation of its corporate identity and a bold...

Chemotherapy and Targeted Therapy

The Psychedelic Paradox: Are We Overestimating the Efficacy of Psilocybin?

Biopharma Mid-Year Pulse: J&J Earnings, Strategic M&A, and the Rise of AI-Driven Drug Discovery

Merck’s ADC Strategy Gains Momentum: Positive Clinical Data Bolsters Sac-TMT as a Future Cancer Standard

From Diabetes to MASH: How the GLP-1 Revolution is Redefining the Biobanking Landscape

Draig Therapeutics Secures $65M Series B to Advance "Best-in-Disease" Psychiatric Pipeline

Moderna’s Second Act: Betting on In Vivo CAR-T, Oncology, and the ‘Lucy’ AI Engine

Convergence at the Crescent City: AAPS PharmSci 360 2026 Set to Define the Future of Drug Development

The New Economics of Medicine: How Most-Favored-Nation Pricing is Reshaping Generic Drug Strategy

The Future of Colorectal Cancer Screening: Freenome and Abbott’s High-Stakes Path to Market Dominance

Evolution in B2B Media: WTWH Media Rebrands as Arrowfly to Reflect Expanded Market Presence

You may have missed

Ibuprofen: Beyond Pain Relief – Unveiling its Unexpected Anti-Cancer Potential

A Paradigm Shift in HIV Care: Gilead and Merck’s Once-Weekly Regimen Passes Phase 3 Milestone

Beyond Wrinkles: The Emerging Role of Botox in Revolutionizing Scar Management

The Radiology Crisis: Escalating Costs and Workforce Shortages Threaten Patient Care